
    
      This is a Phase IB study assessing the safety of 2 cycles of induction (Arm A) nivolumab or
      (Arm B) 2 cycles of induction nivolumab prior to concurrent chemoradiation plus nivolumab
      (Arm A) or nivolumab/relatlimab (Arm B) before surgical resection in operable stage II/III
      esophageal/gastroesophageal junction cancer.

      Approximately 32 patients will be enrolled on study with 16 enrolled on Arm A and if no
      unexpected toxicities then an additional 16 patients will be enrolled on Arm B.
    
  